Interviewed Experts Expect Taxotere to Increase Overall Survival More Than Other Drugs, Including Lupron Depot, in Stage III Prostate Cancer
A Drug That Improves Survival Would Earn a 50 Percent Patient Share in the U.S. and a 40 Percent Patient Share in Europe , According to a New Report from Decision Resources
WALTHAM, Mass., April 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms ...
Free Access to Taxotere Instills New Hope among Early Stage Breast Cancer Patients
National Institute for Health and Clinical Excellence said that 10,000 breast cancer patients who are in their early stage of the disease would be given free access to// Taxotere, a chemotherapy drug.
This drug was initially given to those suffering from late-stage breast cancer. Statistics sai...
FDA Gives Green Signal To Sanofi-Aventis SA's Cancer Drug Taxotere
French drug maker Sanofi-Aventis SA announced on Thursday that the US Food and Drug Administration has approved its cancer drug Taxotere
to treat patients with stomach cancer.// This approval means that Taxotere
can be used in combination with chemotherapy drugs cisplatin and 5-fluorouracil to trea...
Driven by Launch of Emerging Therapies, Overall Prostate Cancer Drug Market Will Increase by $2 Billion Through 2018
..., an achievement attained only by Sanofi-Aventis's taxotere
and, more recently, by the therapeutic cancer vacc...stin will be driven by its use in combination with taxotere
and sales of Alpharadin will be driven by its use ...Resources Analyst Andrew Merron, Ph.D. "The use of taxotere
to treat patients not previously receiving cytotox...
Drug May Extend Life When Breast Cancer Spreads
..."There has been sort of a preconceived notion that taxotere
is the most potent anti-cancer therapy for metasta...h the fourth week off. The fourth group was given taxotere
every three weeks at the standard dose.
Abraxane was found to be generally superior to taxotere
in response rates, but the most striking results w...
Sanofi-aventis Announces Good First-quarter 2009 Performance
...idra (R) SoloSTAR (R) were approved in Japan on April 22, 2009.
Boosted by its use in adjuvant breast cancer treatment and in prostate cancer, taxotere
(R) performed well, especially in Europe and Other Countries, where sales rose by 8.1% (to euro 231 million) and by 18.9% (to euro 106 million) resp...
ADVENTRX Grants Exclusive Rights to ANX-514 in South Korea
... and neck and gastric cancers. In 2007, the aggregate worldwide market for taxotere
was in excess of $3 billion. The market for taxotere
in South Korea was in excess of $30 million in 2007.
"Shin Poong is we...
Sanofi-aventis Delivers 2008 Results Above Guidance
...ales growth in the United States. Our goal is to establish Lantus(R) as the leading anti-diabetic in the world by value.
In the fourth quarter, taxotere
(R) posted another fine performance, especially in the United States where net sales were up 16.9% at EUR 208 million, driven by the product's use i...
If Herceptin is Approved in Combination With Other Emerging Therapies it Will be in a Position to Retain Patient Share From Tykerb/Tyverb for the Treatment of HER2-Positive Breast Cancer
...he/Chugai's Drug in Combination With Herceptin and taxotere
Will Become Decision Resources Gold Standard Regim... in combination with Herceptin and Sanofi Aventis' taxotere
will become Decision Resources' proprietary clinic...r the indication in combination with Herceptin and taxotere
"Based on surveys and interviews we...
AstraZeneca's Drug Will Become the New Clinical Gold Standard by 2012 for the Treatment of Metastatic Hormone-Refractory Prostate Cancer
...s' optimism for zibotentan's Phase II survival data combined with our survey results make zibotentan the most likely agent to supplant Sanofi-Aventis' taxotere
as our gold standard treatment for metastatic hormone-refractory prostate cancer patients," stated Natalia Reoutova, M.Sc., analyst at Decision Resour...
Taxotere in Medical Technology
ADVENTRX Announces Results From ANX-514 Bioequivalence Study
...tration, pharmaceutical equivalence of ANX-514 and taxotere
The bioequivalence study of A...d, randomized, crossover comparison of ANX-514 and taxotere
in patients with advanced cancer potentially sensi...ing the pharmacokinetic equivalence of ANX-514 and taxotere
and determining the safety of a single dose of ANX...
ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
...and neck & gastric cancers. In 2007, the aggregate worldwide market for taxotere
was in excess of $3 billion.
The study is a multi-center, open-label,...tere, with a primary endpoint of pharmacokinetic equivalence of ANX-514 and taxotere
and a goal of 28 evaluable patients. The safety of a single dose of ANX-514...
Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
...ed to evaluate the safety and efficacy of GVAX
immunotherapy for prostate cancer used in combination with Taxotere
chemotherapy compared to the use of taxotere
chemotherapy and prednisone in
HRPC patients with metastatic disease who are symptomatic with
cancer-related pain. The primary endpoint of the trial i...
Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
...zed, controlled Phase 3 clinical trial designed to evaluate the
safety and efficacy of GVAX immunotherapy for prostate cancer used in
combination with taxotere
chemotherapy compared to the use of Taxotere
chemotherapy and prednisone in HRPC patients with metastatic disease who
are symptomatic with cancer-rela...
Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
...rily North American centers,
patients who received taxotere
added to cisplatin and 5-fluorouracil (TPF,
products (EMEA) of the indications for taxotere
in combination with
cisplatin and 5-fluorouracil f...hree cycles either with an intravenous infusion of taxotere
plus cisplatin 100 mg/m(2) on day one a...
Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
...el; Sanofi Aventis) in
patients with solid tumors. taxotere
is an approved chemotherapy agent
marketed for use...cycle to patients with cancer
where treatment with taxotere
is approved or considered standard of care,
or pat...eclinical models that MGCD0103 is synergistic with taxotere
could potentially sensitize and re-sensitize p...
Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
...mpared to 48% in the PF arm. "The TAX 324 trial found that the addition of taxotere
induction chemotherapy significantly improved patient survival,...ncology Program at Dana-Farber
Cancer Institute in Boston. "The approval of taxotere
to be given in
combination with other standard chemotherapy as the first st...
ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic
Testing of ANX-514 (Docetaxel Emulsion)
...icity was observed following dosing with ANX-514 than dosing
with Taxotere. taxotere
induced an anaphylactoid type reaction
consistent with hypersensitivity rea...n 505(b)(2) NDA covering ANX-514, ADVENTRX must certify that
all applicable taxotere
patents have expired prior to the
manufacture, use or sale of ANX-514.
Additional Efficacy Data from Satraplatin SPARC Phase 3
Investigational Trial Presented at Annual Meeting of American
prednisone arm (N=351) compared with 13.8 percent for the placebo
arm (N=181) (p=0.005). Pain response rates for patients treated
with prior taxotere
were 25.7 percent for the satraplatin arm
compared with 13.1 percent for control (p<0.015). All of the
findings presented today continue to build on t...
Additional New Data from Satraplatin SPARC Phase 3 Investigational
Trial Presented at ASCO Annual Meeting
...ogression for patients receiving
satraplatin. These analyses included prior taxotere
geographies, as well as presence or absence of pain.
CHICAGO, June 04...favored satraplatin for
all pre- specified patient subsets, including prior taxotere
geographies, and the presence or absence of pain. For each of the
Taxotere in Biological News
Sunshine pill for prostate cancer in 2009
...ould be expected to take one tablet once a week with their weekly regime of taxotere
for three weeks out of every four.
Business analysts say Asentar is a ... the success of early trials. 'The phase II trial used a less than optimal taxotere
regime so the survival rate may have been artificially inflated,' he says. ...
Taxotere in Biological Technology
The Foundation for National Institutes of Health Announces Unprecedented Product Donation by sanofi-aventis in the U.S.
...s.us or www.sanofi-aventis.com .
Please see the accompanying Eloxatin (oxaliplatin injection), Lovenox (enoxaparin sodium injection), and taxotere
(docetaxel) Injection Concentrate full prescribing information, including Boxed Warnings.
Forward Looking Statements
This press rel...
Sanofi-aventis Announces Second Quarter 2009 Results
...les of the product were up 6.9% at euro 1,542 million.
No biosimilar of Lovenox ((R)) has been approved in the United States to date.
((R)) achieved second-quarter growth of 10.7% to euro 584 million, driven by its use in adjuvant breast cancer treatment and in prostate cancer. Gro...
New Report Just Published: World Prostate Cancer Therapeutics Market Report
...n Localized Prostate Cancer II-61
Balanced Intake of Omega-6 and Omega-3 Fatty Acids Found to
Reduce Prostate Cancer Growth II-62
Gains Approval from Nice of UK for Use in
Late-Stage Prostate Cancer II-62
Protox Gains Clearance from FDA to Conduct Phase I Trial of
ADVENTRX Announces Further Cost-Cutting Measures
...etaxel emulsion for injection) is a reformulation of the blockbuster chemotherapeutic agent, Taxotere(R). In 2007, the aggregate worldwide market for taxotere
was in excess of $3 billion. ANX-530 (vinorelbine injectable emulsion) is a reformulation of Navelbine(R) which, despite being a generic product for ...
ADVENTRX Exploring Strategic Options
.... ANX-514 (docetaxel emulsion) is a reformulation of the blockbuster chemotherapeutic agent, Taxotere(R). In 2007, the aggregate worldwide market for taxotere
was in excess of $3 billion. ANX-530 (vinorelbine emulsion) is a reformulation of Navelbine(R) which, despite being a generic product for a number of ...
First Taxane-Based Non-Anthracycline Containing Chemotherapy in Combination With Herceptin (TCH) for HER2 Positive Early Breast Cancer Patients Obtains Approval From the FDA
...tment of HER2 (Human Epidermal growth factor Receptor
2)-positive early breast cancer. The AC-TH regimen (doxorubicin and
cyclophosphamide followed by taxotere
and Herceptin), also investigated in
the BCIRG 006 study, received approval at the same time.
Results from the BCIRG 006 clinical trial showed that ...
AstraZeneca's Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non-Small-Cell Lung Cancer by 2016
...e opinions of interviewed thought
leaders indicate that Avastin/Taxol/Paraplatin has advantages over the
sales-leading combination of Sanofi-Aventis's taxotere
Squibb's Platinol-AQ on overall survival."
About the Report
Non-Small-Cell Lung Cancer (Advanced): Current Gold-Standard Therapy...
ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
... under the brand name Taxotere(R). Annual sales of taxotere
were approximately $2.2 billion. "We feel...lactoid clinical reactions were
observed following taxotere
administration, including decreased
respiration, s...hat demonstrates the
bioequivalence of ANX-514 and taxotere
is sufficient clinical data to
support filing an N...
Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
... by up to 100 percent. Subsequent testing showed efficacy in
animal models of breast, colon and prostate cancers. The antibody compared
favorably with taxotere
in prostate cancer model and has also shown the
ability to be highly potent at low-dose concentrations. Additional information can be found at the AA...
ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
... cancers, and is marketed under the
brand name Taxotere(R). Annual sales of taxotere
in 2006 were approximately
$2.2 billion. ADVENTRX recently received confir...proximately 28 patients that
demonstrates the bioequivalence of ANX-514 and taxotere
is sufficient to
support filing an NDA. About ANX-514 (docetaxel emulsion)...